The scanners at marketmoveralerts.com, with the help of Tipranks.com, found the following stock rating has recently occurred.
Yigal Nochomovitz analyst at Citigroup reiterates coverage on Rain Therapeutics (RAIN) in the Healthcare sector with a Buy rating. TipRanks.com has Nochomovitz rated as a 4.3 star analyst with a 46% return on investment and a 7.7% success rate. Nochomovitz has set a price target of $ 29.
TipRanks.com reports that Rain Therapeutics currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $18.14. The target pricing ranges from a high forecast of $29.00 down to a low forecast of $12.00. Rain Therapeutics (RAIN)’s last closing price was $10.02 which would put the average price target at 81.04% upside.
In addition, TradingView issued a Buy rating for RAIN over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on RAIN.
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com. Another great tool for charting is TradingView.com, so you might want to check that out too.
Click here to get the full story >>
When an analyst reiterates coverage on RAIN, we will let you know. Please make sure you subscribe to our email newsletter to get timely alerts. Join thousands of other investors, you can always unsubscribe.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
Yigal Nochomovitz analyst at Citigroup reiterates coverage on Rain Therapeutics (RAIN) in the Healthcare sector with a Buy rating. TipRanks.com has Nochomovitz rated as a 4.3 star analyst with a 46% return on investment and a 7.7% success rate. Nochomovitz has set a price target of $ 29.
TipRanks.com reports that Rain Therapeutics currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $18.14. The target pricing ranges from a high forecast of $29.00 down to a low forecast of $12.00. Rain Therapeutics (RAIN)’s last closing price was $10.02 which would put the average price target at 81.04% upside.
In addition, TradingView issued a Buy rating for RAIN over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on RAIN.
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com. Another great tool for charting is TradingView.com, so you might want to check that out too.
Click here to get the full story >>
When an analyst reiterates coverage on RAIN, we will let you know. Please make sure you subscribe to our email newsletter to get timely alerts. Join thousands of other investors, you can always unsubscribe.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
